In part two of our conversation with Memorial Sloan Kettering Cancer Center medical oncologist Dr Eileen O’Reilly, she describes the disease burden among pancreatic cancer patients, which makes it tough for enrolment in clinical trials. Dr O’Reilly also underscores the importance of finding efficiencies in diagnosis to boost patients’ chances of survival.
Previously, Dr O’Reilly described the increasing resonance of preclinical trial data in sculpting clinical trial design, and noted that pharmaceutical companies are gun-shy in diving into a disease space with high unmet need. Read more . . .